Q&A: Pharma/Biotech

Hello everyone!

After being in drug development for a number years, I pivoted to pharma business strategy consulting (clinical portfolio management specifically), and I now run my own consulting firm. My clients are mostly institutional investors and other consulting firms. I really enjoy the process of someone "picking my brain" on anything pharma/biotech - I actually find it more intellectually stimulating than a lot of the things I've done throughout my career. Ask me any anything biotech/pharma - trends, specific drugs/classes, companies etc... - and I will reply (when I can). Happy AMA!

(PS: I can answer anything from a clinical or business strategy perspective, finance is not my strong(est) suit though)

14 Comments
 

My 2 favs (more about biotech than pharma per se):

-The Billion-Dollar Molecule, by Barry Werth

-Genentech: The Beginnings of Biotech, by Sally Smith Hughes

 
Most Helpful

Got a bunch here if you’re willing (not a pharma guy myself)…

How close are you to the funding environment for early stage companies? How are current market conditions impacting the space?

How ‘frothy’ were things really in the recent run-up (through early 2021) in terms of potentially crappy / overly risky companies getting funded? Are we going to see a big wave of bankruptcies / shut downs in next couple years after the crazy IPO & SPAC activity?

Are companies slowing R&D spend a lot due to fear of launching a secondary in the near term?

General appetite amongst your clients for biotech investments amidst rising rates? Preference for later stage / proven assets only?

Cell and gene therapies continuously get brought up as a major new area (from a supplier / manufacturing / service vendor perspective)…your take on the potential of these two areas and quality of the pipeline (maybe too broad a question)?

 

Thank you for this.

A few questions:

  1. How difficult was to brunch out on your own?
  1. How difficult is it to scale? It’s a quite niche space - do you see a lot of competition?
 

Thoughts on companies such as Insitro? Wondering how CRO's will be forced to change as artificial intelligence potentially changes biopharmaceutical R&D processes

 

Cool career background. Congrats on starting your own company. I am a new VC associate. My shop invests in late stage biotech (80% private), but recently started dipping their toes into public markets because of the downturn. I am relied upon to generate pitches / investment thesis and present this information in concise 10-15min presentations. I am wondering if you can give a super rough outline of what the key points you would be interested in hearing in this style of pitch. Obviously TAM, relevant clinical trial outcomes, competitor analysis, SOTP outputs. Is there anything else you would focus on?

 

Error voluptas et saepe sapiente earum. Facere accusamus dolore ut reprehenderit ullam sapiente ducimus debitis. Amet dicta architecto est maxime cum.

Corporis neque voluptas totam. Quidem qui possimus aut accusamus qui.

Laborum officiis quo accusamus laudantium voluptatem et placeat. Officia aliquam et hic dolor officiis voluptate praesentium. Deserunt dolor reprehenderit voluptatem perspiciatis excepturi non. Fugiat eum odio quis esse magni et quaerat.

Est repellat laborum aut temporibus est. Corporis officia aut ratione sit fugit quo non. Aut quam aut dolor at eveniet velit vitae aut. Totam sit incidunt rem fugiat. Facilis ducimus commodi molestias voluptates et. At reiciendis dolor laborum est ut nobis.

charts
Better Odds of Getting Into Hedge Fund With WSO
We help you land the role or you get free tuition.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • Citadel Investment Group 97.1%
  • AQR Capital Management 96.2%
  • Magnetar Capital 95.2%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • Millennium Partners 98.1%
  • D.E. Shaw 97.1%
  • Blackstone Group 96.1%
  • Citadel Investment Group 95.1%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.1%
  • Point72 98.1%
  • D.E. Shaw 97.2%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.3%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $192
  • Analysts (240) $181
  • Intern/Summer Associate (28) $146
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”